AstraZeneca PLC ADR
ISIN US0463531089
|WKN 886715
Overview
Description
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Healthcare Biopharmaceuticals Other Biopharmaceuticals United Kingdom
Chart
Financials
Key metrics
| Market capitalisation, EUR | 227,894.85 m |
| EPS, EUR | 1.92 |
| P/B ratio | 6.37 |
| P/E ratio | 39.05 |
| Dividend yield | 1.79% |
Income statement (2023)
| Revenue, EUR | 42,374.41 m |
| Net income, EUR | 5,508.28 m |
| Profit margin | 13.00% |
What ETF is AstraZeneca PLC ADR in?
There are 19 ETFs which contain AstraZeneca PLC ADR. All of these ETFs are listed in the table below. The ETF with the largest weighting of AstraZeneca PLC ADR is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
| ETF | Weight | Investment focus | Holdings | TER | Fund size (in m EUR) | Return 1Y | WKN | ISIN |
|---|---|---|---|---|---|---|---|---|
| Invesco NASDAQ-100 Equal Weight UCITS ETF Acc | 1.01% | Equity Technology Equal Weighted | 0.20% | 124 | +7.47% | A3EE27 | IE000L2SA8K5 | |
| First Trust Value Line® Dividend Index UCITS ETF Acc | 0.48% | Equity United States Dividend | 0.70% | 15 | +12.22% | A2PZMV | IE00BKVKW020 | |
| WisdomTree Megatrends UCITS ETF USD | 0.07% | Equity World Social/Environmental Innovation | 0.50% | 45 | - | A3EYCN | IE0000902GT6 | |
| Invesco EQQQ Nasdaq-100 UCITS ETF Acc | 0.31% | Equity United States Technology | 0.30% | 2,073 | +18.03% | A2N6RV | IE00BFZXGZ54 | |
| Invesco Nasdaq-100 ESG UCITS ETF Acc | 0.29% | Equity United States Technology Social/Environmental | 0.25% | 1,115 | +19.25% | A3CZGT | IE000COQKPO9 | |
| WisdomTree BioRevolution UCITS ETF USD Acc | 1.15% | Equity World Health Care Social/Environmental Biotech | 0.45% | 3 | -3.26% | A3CY21 | IE000O8KMPM1 | |
| iShares Nasdaq 100 UCITS ETF EUR Hedged Acc | 0.31% | Equity United States Technology | 0.36% | 636 | +18.29% | A2N34W | IE00BYVQ9F29 | |
| iShares Nasdaq 100 UCITS ETF (DE) | 0.31% | Equity United States Technology | 0.31% | 3,884 | +17.82% | A0F5UF | DE000A0F5UF5 | |
| L&G Global Thematic ESG Exclusions UCITS ETF USD Accumulating | 0.71% | Equity World Social/Environmental Innovation | 0.60% | 4 | +1.21% | A3DHPA | IE000VTOHNZ0 | |
| Xtrackers Nasdaq 100 UCITS ETF 1C | 0.32% | Equity United States Technology | 0.20% | 723 | +18.17% | A2QJU3 | IE00BMFKG444 | |
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 3.68% | Equity United States Health Care Biotech | 0.35% | 34 | +13.29% | A2JDYM | IE00BDZVHG35 | |
| iShares Nasdaq US Biotechnology UCITS ETF | 3.68% | Equity United States Health Care Biotech | 0.35% | 480 | +13.41% | A2DWAW | IE00BYXG2H39 | |
| Invesco Nasdaq-100 UCITS ETF EUR Hedged | 0.31% | Equity United States Technology | 0.35% | 225 | +18.67% | A2DT9V | IE00BYVTMS52 | |
| Invesco Nasdaq-100 UCITS ETF CHF Hedged | 0.31% | Equity United States Technology | 0.35% | 311 | +21.23% | A2JAN0 | IE00BYVTMT69 | |
| Invesco Nasdaq-100 UCITS ETF GBP Hedged | 0.31% | Equity United States Technology | 0.35% | 280 | +22.35% | A2JNFA | IE00BYVTMW98 | |
| Deka Nasdaq-100® UCITS ETF | 0.31% | Equity United States Technology | 0.25% | 24 | - | ETFL62 | DE000ETFL623 | |
| L&G Pharma Breakthrough UCITS ETF | 2.83% | Equity World Health Care Innovation | 0.49% | 17 | -3.19% | A2H9XR | IE00BF0H7608 | |
| Invesco EQQQ Nasdaq-100 UCITS ETF | 0.31% | Equity United States Technology | 0.30% | 6,817 | +17.99% | 801498 | IE0032077012 | |
| iShares Nasdaq 100 UCITS ETF (Acc) | 0.31% | Equity United States Technology | 0.33% | 13,041 | +17.99% | A0YEDL | IE00B53SZB19 |
Performance
Returns overview
| YTD | +16.23% |
| 1 month | -2.64% |
| 3 months | -0.47% |
| 6 months | +17.47% |
| 1 year | +17.47% |
| 3 years | +52.13% |
| 5 years | - |
| Since inception (MAX) | +66.68% |
| 2023 | -5.34% |
| 2022 | +30.34% |
| 2021 | - |
| 2020 | - |
Monthly returns in a heat map
Risk
Risk metrics in this section:
- Volatility, annualised, measured for 1, 3 and 5 year periods. The annualised volatility reflects the degree of price fluctuations during a one year period. The higher the volatility, the more significantly the price of the asset (stock, ETF, etc.) has changed in the past. Assets with higher volatility are generally considered more risky. We calculate the volatility based on the data for the past 1, 3 and 5 years so that you can see if price fluctuations for the ETF became stronger or weaker over time.
- Return per risk for 1, 3 and 5 year periods. This is the annualised (i.e. converted to a one year period) past return divided by the past annualised volatility. The metric puts the historical return of an asset in relation to its historical risk and gives you a retrospective indication of the degree of price fluctuation you had to bear with in order to obtain the return. We calculate this parameter for 1, 3 and 5 year periods to display its evolution over time.
- Maximum drawdown for a period. This shows the worst possible loss an investor could have suffered during the respective period, by first buying and subsequently selling the asset at the least favourable prices. For example, if there was the following sequence of daily ETF prices: 10€, 5€, 12€, 20€, an investor would have suffered the worst loss by buying for 10€ and subsequently selling for 5€. Therefore in this case the maximum drawdown would be (5€ - 10€)/10€ = -50%.
Risk overview
| Volatility 1 year | 19.80% |
| Volatility 3 years | 23.40% |
| Volatility 5 years | - |
| Return per risk 1 year | 0.88 |
| Return per risk 3 years | 0.64 |
| Return per risk 5 years | - |
| Maximum drawdown 1 year | -14.33% |
| Maximum drawdown 3 years | -20.92% |
| Maximum drawdown 5 years | - |
| Maximum drawdown since inception | -20.92% |
Rolling 1 year volatility
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.